- Home
- WAT vs BIIB Comparison
WAT vs BIIB Comparison
Compare WAT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAT
- BIIB
- Stock Information
- Founded
- WAT 1958
- BIIB 1978
- Country
- WAT United States
- BIIB United States
- Employees
- WAT N/A
- BIIB N/A
- Industry
- WAT Biotechnology: Laboratory Analytical Instruments
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WAT Industrials
- BIIB Health Care
- Exchange
- WAT Nasdaq
- BIIB Nasdaq
- Market Cap
- WAT 20.1B
- BIIB 18.8B
- IPO Year
- WAT 1995
- BIIB 1991
- Fundamental
- Price
- WAT $348.17
- BIIB $125.00
- Analyst Decision
- WAT Buy
- BIIB Buy
- Analyst Count
- WAT 15
- BIIB 27
- Target Price
- WAT $385.27
- BIIB $188.17
- AVG Volume (30 Days)
- WAT 458.6K
- BIIB 1.3M
- Earning Date
- WAT 07-30-2025
- BIIB 07-31-2025
- Dividend Yield
- WAT N/A
- BIIB N/A
- EPS Growth
- WAT 8.23
- BIIB 26.39
- EPS
- WAT 11.02
- BIIB 10.12
- Revenue
- WAT $2,983,253,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- WAT $6.07
- BIIB N/A
- Revenue Next Year
- WAT $6.41
- BIIB N/A
- P/E Ratio
- WAT $31.91
- BIIB $12.41
- Revenue Growth
- WAT 2.57
- BIIB 1.59
- 52 Week Low
- WAT $279.24
- BIIB $110.04
- 52 Week High
- WAT $423.56
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- WAT 55.88
- BIIB 45.14
- Support Level
- WAT $337.51
- BIIB $123.21
- Resistance Level
- WAT $349.91
- BIIB $129.27
- Average True Range (ATR)
- WAT 7.98
- BIIB 3.00
- MACD
- WAT 0.59
- BIIB -0.77
- Stochastic Oscillator
- WAT 84.15
- BIIB 21.06
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.